Welcome to our dedicated page for United Guardian news (Ticker: UG), a resource for investors and traders seeking the latest updates and insights on United Guardian stock.
United-Guardian, Inc. manufactures specialty ingredients and healthcare products across cosmetic ingredients, personal care and sexual wellness ingredients, pharmaceuticals, and medical lubricants. Company updates commonly cover quarterly and annual operating results, product-category sales trends, cash dividends, and demand for Renacidin, its key pharmaceutical product.
United-Guardian news also discusses distributor activity for cosmetic ingredients, including purchasing patterns at Ashland Specialty Ingredients, international demand conditions, tariff-related pressures, medical lubricant sales, product-development efforts for personal care markets, and board governance updates.
United-Guardian reported increased financial results for Q3 and the first nine months of 2024. Nine-month sales grew from $8.28M to $9.71M, with net income rising from $1.84M ($0.40/share) to $2.75M ($0.60/share). Q3 sales remained stable at $3.06M, while net income increased from $627K ($0.14/share) to $865K ($0.19/share). Cosmetic ingredients sales rose 8% in Q3 and 68% in the first nine months. Medical lubricants saw a 2% Q3 decrease but 4% nine-month growth. Pharmaceutical sales declined 6% in Q3 and 11% over nine months due to a Renacidin® supply disruption.
United-Guardian (NASDAQ:UG) reported strong financial results for Q2 and H1 2024. Sales for H1 2024 increased to $6,645,149 from $5,220,623 in 2023, while net income rose to $1,881,667 ($0.41 per share) from $1,217,175 ($0.26 per share). Q2 2024 sales grew to $3,390,205 from $2,650,299 in 2023, with net income increasing to $956,225 ($0.21 per share) from $461,094 ($0.10 per share).
Key highlights include:
- Cosmetic ingredient sales up 84% in Q2 and 115% in H1 2024
- Medical lubricant sales increased 15% in Q2 and 9% in H1 2024
- Pharmaceutical product sales up 3% in Q2 but down 13% in H1 2024 due to a temporary shutdown
The company attributes the growth to increased purchases from its largest cosmetic distributor and recovering Renacidin® sales after production resumed in late March.
United-Guardian (NASDAQ: UG) announced a cash dividend of $0.35 per share, payable on July 31, 2024, to stockholders of record as of July 23, 2024. This marks the 29th consecutive year of dividend payments by the company.
The dividend represents a 40% increase over the $0.25 per share paid earlier this year and a 250% increase over the $0.10 dividend paid last July. President Donna Vigilante emphasized the balance between supporting growth initiatives and providing strong dividends to stockholders.
United-Guardian manufactures cosmetic ingredients, medical lubricants, sexual wellness ingredients, and pharmaceuticals.
United-Guardian (NASDAQ:UG) announced the hiring of Denise Costrini as the new marketing director. Ms. Costrini brings over 25 years of experience in the personal care and specialty chemicals industries. She holds a Bachelor of Science degree in Industrial and Operations Engineering and has expertise in strategic market planning and new product commercialization. The company believes her background in market assessment, brand positioning, and new business development will enhance market penetration and international growth, particularly in areas with significant expansion opportunities.
United-Guardian, Inc. (NASDAQ:UG) reported increased first quarter sales and earnings for 2024. Sales rose from $2,570,324 in 2023 to $3,254,944 in 2024, with net income increasing from $756,081 to $925,442. Cosmetic ingredients sales surged by 146%, driven by increased purchases from their largest distributor, ASI. However, pharmaceutical sales declined by 30% due to a temporary shutdown at a contract manufacturer's facility affecting Renacidin® sales. Production has since resumed, and orders are being fulfilled since March.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.